Sialylation pathway enzymes

The sialylation pathway enzymes are a group of proteins responsible for the biosynthesis, activation, and transfer of sialic acids to the terminal ends of glycoconjugates [1.1.1, 1.4.1]. This pathway includes the rate-limiting enzyme UDP-GlcNAc 2-epimerase/N-acetylmannosamine kinase (GNE), various sialyltransferases (STs) located in the Golgi apparatus, and sialidases (neuraminidases) that catalyze the removal of sialic acid residues [1.1.1, 1.6.2]. Sialylation is critical for diverse biological processes, including cell-cell recognition, immune signaling through Siglec receptors, and maintaining the structural integrity of the glycocalyx [1.1.4, 1.4.3]. Dysregulation of these enzymes is linked to several pathologies, most notably the hypersialylation of tumor cells which facilitates metastasis and immune evasion, and viral infections where neuraminidase is essential for the release of new virions [1.3.1, 1.4.2, 1.6.1]. Therapeutic strategies targeting this pathway include the use of neuraminidase inhibitors like oseltamivir for influenza and the development of sialyltransferase inhibitors for cancer, as well as substrate replacement therapies for genetic disorders like GNE myopathy [1.2.1, 1.3.3, 1.5.3]. These enzymes represent a complex but vital set of targets for modulating cell surface interactions and metabolic homeostasis.

Other names

Sialic acid metabolism enzymesSialic acid biosynthetic pathway enzymesSialidasesSialyltransferasesNeuraminidasesGNE/MNK

The primary mechanisms include the competitive inhibition of viral neuraminidase to prevent the release of progeny virions from host cells, the inhibition of sialyltransferases to reduce aberrant cell-surface hypersialylation in malignant cells, and the provision of metabolic precursors to bypass enzymatic blocks in sialic acid biosynthesis.